Non Hodgkin's lymphoma--diagnosis and management

Major advances have been made in the treatment of NHL but many problems still remain. New and improved forms of treatment are required for patients with low-grade NHL, most of whom cannot be cured. For patients with aggressive NHL, the haematopoietic growth factors offer the chance of reducing the morbidity and maintaining the intensity of treatment. This should translate to improved long-term outcome. Well designed clinical trials need to be done to answer many remaining questions in the treatment of this potentially curable group of diseases.